ScreenerHero
VEXTVext Science Inc.
CNQ · CA · Healthcare · Drug Manufacturers - Specialty & Generic · vextscience.com
0.2550CADMkt Cap: 46.00M $P/E: —

Vext Science, Inc., through its subsidiaries, engages in integrated cannabis operations in the United States. It owns and manages cultivation facilities, manufacturing units, and dispensaries; and involves in the cultiva…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.24BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.37BUSDP/E 12.4
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.5
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.34BUSDP/E 16.6
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap46.00M $
Enterprise Value73.92M $
Revenue (TTM)37.84M $
Gross Profit10.53M $
Net Income (TTM)-13.10M $
Revenue/Share0.1529 USD
Last Price0.2550 CAD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees—
CountryCA
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINCA9255401064
Valuation
P/E (Trailing)—
P/E (Forward)-7.38
PEG—
EV/EBITDA10.16
EV/Revenue1.95
P/S1.41
P/B0.97
EPS (TTM)-0.08
EPS (Forward)-0.04
52W Range
0.2450100% of range0.2550
52W High0.2550 CAD
52W Low0.2450 CAD
Profitability
Gross Margin28.14%
Oper. Margin0.00%
EBITDA Margin19.23%
Profit Margin-35.03%
ROE-32.50%
ROA-14.93%
Growth
Revenue Growth5.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF8.53M $
CapEx (TTM)2.60M $
FCF Margin41.48%
FCF Yield34.13%
Net Debt20.70M $
Net Debt/EBITDA2.84
Balance Sheet
Debt/Equity0.63
Current Ratio0.62
Quick Ratio0.23
Book Value/Sh0.3052 CAD
Cash/Share0.0220 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CAD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)0.9500 CAD
Upside (mean)+272.5%
Target Range0.9500 CAD – 0.9500 CAD
# Analysts1
Ownership
Shares Out.185.79M
Float101.64M
Insiders45.69%
Institutions0.35%
Short Interest
Short Ratio0.0d
Short % Out.0.00%
Shares Short559
Short (prev mo.)14.52K
Technical
SMA 500.2507 (+1.7%)
SMA 2000.2625 (-2.9%)
Beta0.80
S&P 52W Chg18.16%
Avg Vol (30d)16.00K
Avg Vol (10d)28.89K
Technical Indicators
RSI (14)54.9
MACD0.0002
MACD Signal-0.0011
MACD Hist.+0.0013
BB Upper0.2639 CAD
BB Middle0.2457 CAD
BB Lower0.2276 CAD
BB Width14.77%
ATR (14)0.0099 CAD
Vol Ratio (20d)3.56x